Glen Wheeler

Summary

Publications

  1. ncbi Repifermin. Human Genome Sciences/GlaxoSmithKline
    G Wheeler
    IDrugs 4:813-9. 2001
  2. ncbi ADL-2-1294 (Adolor)
    G D Wheeler
    IDrugs 3:1373-8. 2000
  3. ncbi Gabapentin. Pfizer
    Glen Wheeler
    Curr Opin Investig Drugs 3:470-7. 2002
  4. ncbi RG-1068 RepliGen
    Glen Wheeler
    Curr Opin Investig Drugs 4:66-71. 2003
  5. ncbi Ruboxistaurin (Eli Lilly)
    Glen D Wheeler
    102 711 West 17th Avenue, Vancouver, BC V5Z 1V1, Canada
    IDrugs 6:159-63. 2003

Detail Information

Publications5

  1. ncbi Repifermin. Human Genome Sciences/GlaxoSmithKline
    G Wheeler
    IDrugs 4:813-9. 2001
    ..Overall, the analysts estimated that repifermin represented a 3.5 billion dollars market opportunity for HGS/ GlaxoSmthKline and that commercialization of the drug might earn more than 61 million dollars by 2004 [412015]...
  2. ncbi ADL-2-1294 (Adolor)
    G D Wheeler
    IDrugs 3:1373-8. 2000
    ..The company was issued US-05849761 and US-05849762 in January 1999 covering the use of antidiarrheal opioid compounds for the treatment of inflammatory pain and the treatment of pruritus...
  3. ncbi Gabapentin. Pfizer
    Glen Wheeler
    Curr Opin Investig Drugs 3:470-7. 2002
    ..In September 2001, Morgan Stanley predicted sales of US $1871 million in 2002 falling to US $413 million in 2006...
  4. ncbi RG-1068 RepliGen
    Glen Wheeler
    Curr Opin Investig Drugs 4:66-71. 2003
    ..RG-1068 received Fast Track designation for the treatment of pediatric autism in September 2001, and in February 2002, it entered phase III clinical trials...
  5. ncbi Ruboxistaurin (Eli Lilly)
    Glen D Wheeler
    102 711 West 17th Avenue, Vancouver, BC V5Z 1V1, Canada
    IDrugs 6:159-63. 2003
    ....